SCHEMBL15660790

SCHEMBL15660790

CCc1c(Cl)cc(-c2cccc(Cl)c2)nc1C

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 1/20 0.46
▸ CTSK P43235 1/20 0.46
▸ DPP4 P27487 2/20 0.45
▸ DPP8 Q6V1X1 2/20 0.45
▸ DPP9 Q86TI2 2/20 0.45
▸ DHFR P00374 1/20 0.43
▸ TLR8 Q9NR97 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ IDO1 P14902 1/20 0.40
▸ ADORA3 P0DMS8 1/20 0.39
▸ NOTUM Q6P988 1/20 0.39
▸ USP7 Q93009 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ APOBEC3G Q9HC16 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16669327 0.98 CTSS (0.45) CTSSCTSKDPP4DPP8DPP9
Hydrochloric Acid SCHEMBL29710395 0.98 CTSS (0.45) CTSSCTSKDPP4DPP8DPP9
SCHEMBL20632252 0.72 MAP4K4 (0.51) KMT2AIDO1
SCHEMBL15658078 0.72 PDE4B (0.57) CTSSCTSK
SCHEMBL11253872 0.72 RAC1 (0.43) CTSSCTSKIDO1
SCHEMBL15662218 0.72 CTSS (0.48) CTSSCTSKDHFRTLR8IDO1
SCHEMBL16629543 0.71 CTSS (0.50) CTSSCTSKDHFRTLR8CYP1A2
SCHEMBL16682852 0.70 NPC1 (0.47) CTSSCTSKMEN1KMT2AIDO1
SCHEMBL28396758 0.70 CTSS (0.49) CTSSCTSKDHFRTLR8CYP1A2
SCHEMBL1258335 0.69 MEN1 (0.50) CTSSCTSKMEN1KMT2AIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12264169-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners (US) 2025-04-01 — — US disclosed
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-11-02 — — US disclosed
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-11-02 — — US disclosed
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-11-02 — — US disclosed
US-11767334-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2023-09-26 — — US disclosed
US-11767334-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2023-09-26 — — US disclosed
US-11767334-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2023-09-26 — — US disclosed
US-20230024240-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-01-26 — — US disclosed
US-20230024240-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-01-26 — — US disclosed
EP-3842420-B1 HETEROARYL INHIBITORS OF PDE4 TETRA DISCOVERY PARTNERS LLC (US) 2022-12-07 — — EP disclosed
US-9221843-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2015-12-29 — — US disclosed
US-9221843-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2015-12-29 — — US disclosed
US-9221843-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2015-12-29 — — US disclosed
EP-2912019-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners LLC (US) 2015-09-02 — — EP disclosed
US-20150119362-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2015-04-30 — — US disclosed
US-20150119362-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2015-04-30 — — US disclosed
US-20150119362-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2015-04-30 — — US disclosed
WO-2014066659-A9 HETEROARYL INHIBITORS OF PDE4 TETRA DISCOVERY PARTNERS, LLC. (US) 2015-02-12 — — WO disclosed
WO-2014066659-A9 HETEROARYL INHIBITORS OF PDE4 TETRA DISCOVERY PARTNERS, LLC. (US) 2015-02-12 — — WO disclosed
WO-2014066659-A1 HETEROARYL INHIBITORS OF PDE4 TETRA DISCOVERY PARTNERS, LLC. (US) 2014-05-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230024240-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C CTSS 1316/4885CTSK 1206/4885DPP4 22/4885
US-20150119362-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C CTSS 1710/4885CTSK 1706/4885DPP4 26/4885
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C CTSS 1316/4885CTSK 1206/4885DPP4 22/4885
US-11767334-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C CTSS 1316/4885CTSK 1206/4885DPP4 22/4885
US-12264169-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C CTSS 1316/4885CTSK 1206/4885DPP4 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback